How are NovaBridge Biosciences (NBP) Ordinary Shares related to ADSs in this filing?

The filing explains that NovaBridge Biosciences Ordinary Shares may be represented by American Depositary Shares, or ADSs. Each 10 ADSs represent 23 Ordinary Shares, and the reported securities and RSUs in this Form 4 are referenced in terms of ADSs in the footnotes.

NovaBridge SVP sells shares after exercising awards

NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported a mix of derivative exercises and a small open‑market sale of company stock.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

NovaBridge Biosciences SVP, Clinical Development Xu Cong Claire reported a mix of derivative exercises and a small open‑market sale of company stock. On June 1, 2026, she sold 3,494 Ordinary Shares at an average price of $3.94 per share in an open‑market transaction. On May 30, 2026, she exercised derivative awards to acquire additional Ordinary Shares, including Restricted Share Units (RSUs) covering 4,079 Ordinary Shares. After these transactions, she directly owns 290,154 Ordinary Shares and 32,637 RSUs. Footnotes state that Ordinary Shares are represented by American Depositary Shares (ADSs), where each 10 ADSs represent 23 Ordinary Shares, and her reported holdings correspond to 126,154 ADSs.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Xu Cong Claire

Role SVP, Clinical Development

Sold 3,494 shs ($14K)

Approx. gross sale proceeds $14K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3,494	$3.94	$14K
Exercise	Restricted Share Units	4,079	$0.00	$0.00
Exercise	Ordinary Shares	9,382	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 32,637 contracts (Direct); Ordinary Shares — 290,154 shares (Direct)

Footnotes (9)

F1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
F2. Reported securities are represented by 4,079 ADSs.
F3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.
F4. Reported securities are represented by 127,673 ADSs.
F5. Reported securities are represented by 1,519 ADSs.
F6. Reported sales price represents the converted sales price of the ADSs of $1.71.
F7. Reported securities are represented by 126,154 ADSs.
F8. Reported securities represent ADSs.
F9. On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

Key Figures

Shares sold: 3,494 Ordinary Shares Sale price: $3.94 per share Shares after sale: 290,154 Ordinary Shares +5 more

8 metrics

Shares sold 3,494 Ordinary Shares Open‑market sale on June 1, 2026

Sale price $3.94 per share Average price for 3,494 Ordinary Shares sold

Shares after sale 290,154 Ordinary Shares Direct holdings following reported transactions

RSUs remaining 32,637 RSUs Restricted Share Units held after transactions

RSUs exercised 4,079 RSUs RSUs exercised as derivative awards on May 30, 2026

Initial RSU grant 65,270 RSUs Grant on May 30, 2024 vesting over four years

ADS to Ordinary ratio 10 ADSs = 23 Ordinary Shares Representation of Ordinary Shares by ADSs

ADS equivalent holdings 126,154 ADSs ADSs representing reported securities after transactions

Key Terms

Restricted Share Units, American Depositary Shares, derivative security, open-market sale, +1 more

5 terms

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares ("ADS")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

contingent right financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one ADS."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NovaBridge Biosciences (NBP) report for Xu Cong Claire?

NovaBridge Biosciences reported that SVP Xu Cong Claire exercised derivative awards on May 30, 2026 and then sold 3,494 Ordinary Shares on June 1, 2026. The sale was an open‑market transaction at an average price of $3.94 per share.

How many NovaBridge Biosciences (NBP) shares did the insider sell and at what price?

Xu Cong Claire sold 3,494 Ordinary Shares of NovaBridge Biosciences at an average price of $3.94 per share. This open‑market sale followed recent derivative exercises that increased her Ordinary Share holdings before the sale.

What derivative awards did the NovaBridge Biosciences (NBP) executive exercise?

On May 30, 2026, Xu Cong Claire exercised derivative awards, including Restricted Share Units covering 4,079 Ordinary Shares. These exercises increased her direct equity exposure before she sold a smaller number of Ordinary Shares days later.

What are Xu Cong Claire’s holdings in NovaBridge Biosciences (NBP) after the transactions?

Following the reported transactions, Xu Cong Claire directly holds 290,154 Ordinary Shares and 32,637 Restricted Share Units. Footnotes state these positions are represented in American Depositary Shares equivalent to 126,154 ADSs based on the company’s ADS ratio.

What RSU grant history does the NovaBridge Biosciences (NBP) filing describe?

The filing notes that on May 30, 2024, Xu Cong Claire was granted 65,270 Restricted Share Units. These RSUs vest over four years, with one‑fourth on the first anniversary and the remainder vesting quarterly over the following 12 quarters.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/02/2026 - 06:46 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Cong Claire

(Last)

(First)

(Middle)

C/O NOVABRIDGE BIOSCIENCES

2440 RESEARCH BOULEVARD, SUITE 400

(Street)

ROCKVILLE

MARYLAND

20850

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Clinical Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	05/30/2026		M		9,382⁽²⁾	A	⁽³⁾	293,648⁽⁴⁾	D
Ordinary Shares⁽¹⁾	06/01/2026		S		3,494⁽⁵⁾	D	$3.94⁽⁶⁾	290,154⁽⁷⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽³⁾	05/30/2026		M			4,079⁽⁸⁾	⁽⁹⁾	⁽⁹⁾	Ordinary Shares⁽¹⁾	4,079⁽⁸⁾	$0	32,637⁽⁸⁾	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer.

2. Reported securities are represented by 4,079 ADSs.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one ADS.

4. Reported securities are represented by 127,673 ADSs.

5. Reported securities are represented by 1,519 ADSs.

6. Reported sales price represents the converted sales price of the ADSs of $1.71.

7. Reported securities are represented by 126,154 ADSs.

8. Reported securities represent ADSs.

9. On May 30, 2024, the Reporting Person was granted 65,270 RSUs. The RSUs vested or shall vest over four years, with one-fourth vesting on the first anniversary of the grant date and the balance vesting ratably over the subsequent 12 quarters on the 30th day of each third month.

	/s/ Xi-Yong (Sean) Fu as attorney-in-fact	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR